Chiral HPLC Method Development and Validation for Content Of S-Isomer in Fezolinetant on Cellulose Based Stationary Phase
DOI:
https://doi.org/10.47392/IRJAEM.2026.0354Keywords:
Antagonist, Chiralpak IB, Fezolinetant (R) isomer (RFZL), Fezolinetant (S) isomer (SFZL), ICH Q2(R1) guidelinesAbstract
Fezolinetant (RFZL) is a small molecule, selective neurokinin-3 (NK3) receptor antagonist recommended for the management of menopausal vasomotor symptoms (hot flashes). In the proposed research work, a normal-phase HPLC method was developed for content of Fezolinetant (S) isomer (SFZL) in Fezolinetant (R) isomer (RFZL) and validated in accordance with ICH Q2(R1) guidelines. Satisfactory resolution of the enantiomer was achieved using a Chiralpak IB chiral stationary phase. The mobile phase consisted of a 70:30 (v/v) mixture of n-hexane and ethanol 70:30 (v/v), operated in isocratic mode at a flow rate of 1.0 mL/min. The column temperature was maintained at 45°C, and the total analysis run time was 15 minutes. The developed method was fully validated and demonstrated to be suitable for the quantitative determination of the Fezolinetant (S) isomer (SFZL) in Fezolinetant (R) isomer (RFZL). Linearity for Fezolinetant (S) isomer (SFZL) was plotted with concentration between 0.67 µg/ml to 13.3 µg/ml. Limit of quantification and limit of detection of Fezolinetant (S) isomer (SFZL) were determined 0.67 µg/ml and 0.22 µg/ml respectively and average recovery of Fezolinetant (S) isomer (SFZL) in Fezolinetant (R) isomer (RFZL) was 100% ± 4%. Newly developed normal phase HPLC method was successfully adopted to control Fezolinetant (S) isomer (SFZL) in Fezolinetant (R) isomer (RFZL). by HPLC.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Research Journal on Advanced Engineering and Management (IRJAEM)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.